Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Last updated: October 27, 2026
Sponsor: Children's Hospital Medical Center, Cincinnati
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Myeloid Leukemia

Lymphoma

Hematologic Neoplasms

Treatment

1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.

Clinical Study ID

NCT06131801
Venetoclax PK
  • Ages < 38
  • All Genders

Study Summary

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.

Primary Objectives

• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution

Secondary Objectives

  • To evaluate the safety of crushed venetoclax tablets administered as an oral solution

  • To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors

  • To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)

  • To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age: Patients must be <39 years of age at time of study enrollment

  • Diagnosis: Patients may have a diagnosis of any hematologic malignancy

  • Central access: Patients must have an existing venous or arterial access line for PKblood draws

  • Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment

  • Venetoclax: Patients must be receiving any dose of venetoclax given as a solutionmade from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube asprescribed by their treating oncologist.

  • Concurrent chemotherapy medications: Patients may receive venetoclax as a singleagent or in combination with any other chemotherapeutic agents.

Exclusion

Exclusion Criteria:

  • Pregnant women are excluded from this study because venetoclax has the potential forteratogenic or abortifacient effects. Because there is an unknown but potential riskfor adverse events in nursing infants secondary to treatment of the mother withvenetoclax, breastfeeding should be discontinued if the mother is treated withvenetoclax.

  • Males or females of reproductive potential may not participate unless they haveagreed to use an effective contraceptive method while on study treatment and for sixmonths following completion.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
Phase:
Study Start date:
November 15, 2023
Estimated Completion Date:
December 01, 2027

Study Description

Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.

Connect with a study center

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Active - Recruiting

  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital

    Atlanta, Georgia 30329
    United States

    Site Not Available

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Active - Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • Texas Children's Hospital

    Houston, Texas 77030
    United States

    Active - Recruiting

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.